

# OSP3

## 3<sup>rd</sup> Global Open Source Pharma Conference *Science, License, Community*

### Location:

Center for Research and  
Interdisciplinarity (CRI)  
University of Paris  
Paris, France

### Date:

March 21-23, 2019

### Number of Attendees:

Small (~50) select group of the world's  
thought leaders, feeding significant  
“live” social media outreach

### Overview:

#### **Affordable new medicines are a grand challenge of our time.**

The Open Source Pharma Conference (“OSP3”), is a singular gathering of researchers, NGOs, industry professionals, funders, and entrepreneurs who want to further improve the ways of delivering affordable therapeutics to market in the 21<sup>st</sup> century.


We come from across continents, stages of the drug discovery process, and fields. We hail from the worlds of informatics, business, open source theory, activism, law, art, media, rare and neglected disease, radical pharma innovation, small and big pharma, government, universities, patient communities, NGOs, and multilaterals. Open source brings the promise of efficient, robust and inclusive routes to drug discovery. Using computing, crowdsourcing, big data, data transparency, and open IP, OSP is an alternate paradigm for pharmaceutical innovation. It is a glimpse of the future.

This meeting follows the first global Open Source Pharma (OSP) conference, which took place at the Rockefeller Foundation Bellagio Center, Lake Como, Italy in 2014, and the second, which took place at the Castle Rauischholzhausen, Marburg, Germany in 2015.

The aim of the meeting is to:

- 1) Bond. Nurture the growing community involved in open source-type approaches to drug development
- 2) Develop an Open Source Pharma License? Convene law professors, lawyers, philosophers, and other thinkers in a mini-conference to explore open intellectual property issues and discuss and develop an open source license or set of licenses or other IP set of arrangements for the pharma sector, perhaps analogous to GNU, copyleft, and other licenses in software and other fields.
- 3) Ally. Form scientific and other partnerships among attendees.
- 4) Develop Business Models. How can open source approaches generate revenue, save cost, realize EBITDA?
- 5) Learn. Gain knowledge of current and future efforts, and how open source principles and techniques apply to drug discovery.
- 6) Reflect. What are the myriad challenges facing open source pharma, and how can they be addressed?
- 7) Plan. Hatch ideas for taking the field and movement of open source pharma forward.

**The OSP3 meeting  
is sponsored by  
CRI Research, with  
support from  
DRUID – Giessen  
University.**



### Partners:

CRI-Paris, Cures Within Reach, DRUID, European & Developing Countries Clinical Trials Partnership, Mayo Clinic Center for Tuberculosis, Open Source Malaria, Open Source Pharma Foundation, Philipps-University Marburg, Sage Bionetworks, Tata Trusts

## Committed Participants:

- **Eric Anderson** (Artist in Residence, Open Source Pharma Foundation, Rochester)
- **Urmil Bajpai** (University of Delhi, Delhi)
- **Bryn Bellomy** (Conscience Inc., New York)
- **Mostapha Benhenda** (Founder, Startcrowd, San Francisco)
- **Peter Beyer** (Department of Essential Medicines and Pharmaceuticals, WHO, Geneva) (by video)
- **Anshu Bhardwaj** (Center for Research and Interdisciplinarity, Paris)
- **Marc Bianciotto** (Sanofi, Paris)
- **Anneke Blackburn** (Australian National University, Canberra)
- **Bruce Bloom** (CEO, Cures Within Reach, Chicago)
- **Nadine Bongaerts** (Center for Research and Interdisciplinarity, Paris)
- **Samir Brahmachari** (Founder, Open Source Drug Discovery; AcSIR, Delhi)
- **Tanusree Chaudhuri** (Open Source Pharma Foundation, Bangalore)
- **Karmen Condic-Jurkic** (Open Force Field Consortium, Zagreb)
- **Julia Daniel** (Stanford University, Stanford)
- **Anjana Dhar Koul** (Janssen, Beerse)
- **Keith Elliston** (i2b2/transSMART; Open Source Pharma Foundation, Boston)
- **Nicole Foti** (Open Insulin Project, San Francisco)
- **Stephen Friend** (Chair, Sage Bionetworks; ex senior VP, Merck, Seattle)
- **Bareket Gelbhart** (Gelbhart Innovations, Lugano)
- **Lee Hartwell** (Nobel Laureate; Arizona State University, Arizona) (by video)
- **Melanie Heard** (Center for Research and Interdisciplinarity, Paris)
- **Martin Hetu** (HEC, Paris)
- **UCA Jaleel** (Principal Scientist, Open Source Pharma Foundation, Bangalore)
- **Linda Kahl** (Senior Counsel & Director of Ownership and Innovation, BioBricks, San Francisco)
- **Paul Kohlhaas** (Molecule, Basel)
- **Peter Kolb** (Philipps University-Marburg, Marburg)
- **Thomas Landrain** (Just One Giant Lab, Paris)
- **Ariel Lindner** (Co-founder, Center for Research and Interdisciplinarity, Paris)
- **Amanda McPherson** (Linux Foundation, San Francisco)
- **Jaykumar Menon** (Harvard University, Boston; Open Source Pharma Foundation, Bangalore)
- **Bernard Munos** (FasterCures; Forbes; ex-Eli Lilly, Indiana)
- **Bose Natarajan** (Science Advisor, Bill Gates; bgC3/Gates Ventures, Seattle)
- **Ganesh Neelam** (Tata Trusts, Mumbai)
- **Niclas Nilsson** (LEO Pharma, Ballerup)
- **Ole Oleson** (European & Developing Countries Clinical Trials Partnership, Amsterdam)
- **Ochoro Otunnu** (Founder, Africa Aids Initiative, Africa Center for Democracy, New York)
- **Benjamin Perry** (Senior Discovery Manager, Drugs for Neglected Diseases Initiative, Geneva)
- **Arti Rai** (Duke Law School, North Carolina)
- **Nibedita Rath** (Scientific Director, Open Source Pharma Foundation, Bangalore)
- **Guy Rouleau** (Director, Montreal Neurological Institute and Hospital, McGill University, Montreal)
- **Tomasz Sablinski** (CEO, Transparency Life Sciences, New York) (by video)
- **William Scott** (Professor, IUPUI - Indiana University-Purdue University Indianapolis, Indiana)
- **Anne-Marie Shand** (Taylor & Francis, Oxford)
- **Sitta Sittampalam** (Senior Advisor, National Center for Advancing Translational Sciences, Maryland)
- **Geoffrey Siwo** (University of Notre Dame, Indiana)
- **Ellen 't Hoen** (Medicines Law & Policy, Amsterdam)
- **Zelalem Temesgen** (Head, Mayo Clinic Center for Tuberculosis, Minnesota)
- **Matthew Todd** (University College London; Founder, Open Source Malaria, London)
- **Andy Updegrove** (Gesmer Updegrove LLP, Boston)
- **John Wilbanks** (Sage Bionetworks, Seattle)
- **Alice Williamson** (University of Sydney, Sydney)
- **Jake Wintermute** (Center for Research and Interdisciplinarity, Paris)

## Venue:

The newly renovated building of CRI, a global leader in open science and quantitative approaches to biology, situated in the heart of Paris.

## Organizing Contacts:

**Wengsi Chiu** - [wengsi.chiu@mail.mcgill.ca](mailto:wengsi.chiu@mail.mcgill.ca)

**Alina Grenier-Arellano** - [alina.grenierarellano@mail.mcgill.ca](mailto:alina.grenierarellano@mail.mcgill.ca)

**Peter Kolb** - [peter.kolb@uni-marburg.de](mailto:peter.kolb@uni-marburg.de)

**Ariel Lindner** - [ariel.lindner@inserm.fr](mailto:ariel.lindner@inserm.fr)

**Jaykumar Menon** - [jmenon@hsph.harvard.edu](mailto:jmenon@hsph.harvard.edu)

**Matthew Todd** - [matthew.todd@ucl.ac.uk](mailto:matthew.todd@ucl.ac.uk)

For more information, please visit:

[www.opensourcepharma.net/paris-2019.html](http://www.opensourcepharma.net/paris-2019.html)